Back to the main directory
Company Analysis / Equity
- Balance sheet boosted, but sales may take longer time to gain traction move to Neutral by Zacks
- Continued Positive Data Support PCT In Forensic Application by Zacks
- Novel SDC antimicrobial platform technology targeting diverse large markets by Zacks
- PBSV : New Revenue Catalysts in the Pipeline by Zacks
- PBSV: Lab Segment Remains Robust, Reflecting Opportunistic Investments by Zacks
- PBSV: Maintaining Outperform Rating by Zacks
- PBSV: Q2 Inline. Positive Net Income, Cash Flow Continues by Zacks
- PBSV: Results Remains Soft, Continue to Look For Growth in 2015 by Zacks
- PBSV: Revenue Returns to Sequential Growth, Solid EPS, Cash Flow. Reiterate Buy Rec by Zacks
- PBSV: Still Generating Major Cash Despite Slip in Revenue by Zacks
- Impressive Revenue Growth, Rock Solid Balance Sheet. Initiating At Outperform. by Zacks
- PURE: Balance sheet remains strong, Withdrawal of FCN has only limited short term impact on revenue growth; strong revenue growth is still expected in fiscal 2015 and beyond maintaining Outperform by Zacks
- PURE: FCN resubmitted, strong revenue growth is expected in fiscal 2015 and beyond maintaining Buy rating by Zacks
- PURE Is Recovering From Sales Slump by Zacks
- PURE: PURE Control for Produce is launched in calendar 1Q16, strong revenue growth is expected in fiscal 2016 and beyond maintaining Buy rating by Zacks
- PURE Reports Better Than Expected Revenue in 1Q2012 by Zacks
- PURE: Strong financials reported for fiscal 2Q15, Balance sheet remains strong, strong revenue growth is still expected in fiscal 2015 and beyond maintaining Outperform by Zacks
- PURE: Strong revenue growth is expected in fiscal 4Q14 and beyond, a reborn company with new focus on food safety Outperform by Zacks
- PURE: Update on Fiscal Third Quarter 2016 Financials by Zacks
- PURE: A reborn company with new focus on food safety, growth expected to resume in 2014 upgrading to Outperform by Zacks
- Pressure BioSciences Is Featured In Two Prestigious Magazines by Zacks
- Pressure BioSciences Reports Fiscal Year Results by Zacks
- Pressure Cycling Technology- Continued Push Into New Applications by Zacks
- Q1 Results. FDA OK's Add'l Trial by Zacks
- Q2 Results. Supplemental Trial On Track by Zacks
- Change price target after reverse stock split by Zacks
- New Products Launches are on the Horizon by Zacks
- PBIO Reports Better Than Estimated Third Quarter Financial Results by Zacks
- PBSV: Impressive Cash Flow Despite Lingering Revenue Softness by Zacks
- PBSV: Lab Segment Remains Robust, Reflecting Opportunistic Investments by Zacks
- PBSV: Positive Cash Flow, Trading Below Book Value, Opportune Time to Buy the Stock by Zacks
- PBSV: Q4 Revenue In-Line, Beat on EPS. by Zacks
- PBSV: Revenue Returns to Sequential Growth, Solid EPS, Cash Flow. Reiterate Buy Rec by Zacks
- PBSV: Revenue Soft But Cash Flow Positive. New Investments Could Spark Growth. Trading Below Book Value by Zacks
- PBSV: Record Revenue, Net Income. Shares Remain Cheap by Zacks
- Fiscal Q3 Results In-Line. Maintaining $4.00 Target, Outperform by Zacks
- PURE Exits Quarter With Strong Balance Sheet by Zacks
- PURE: Fiscal 1Q17 Revenue increased 186% YOY, the launch of PURE Control will accelerate revenue growth in calendar 2017 and beyond by Zacks
- PURE: PURE Control for Produce and Poultry is expected to be launched in calendar 1Q16, strong revenue growth is expected in fiscal 2016 and beyond maintaining Buy rating by Zacks
- PURE: PURE Control is expected to be launched in calendar 1Q16, strong revenue growth is expected in fiscal 2016 and beyond maintaining Buy rating by Zacks
- PURE: Sales picked up steam in fiscal 3Q14 and growth will accelerate in calendar 2H14, a reborn company with new focus on food safety Outperform by Zacks
- PURE: Strong revenue growth is expected in fiscal 2015 and beyond, a reborn company with new focus on food safety Outperform by Zacks
- PURE: The launch of PURE Control for Produce will accelerate strong revenue growth in calendar 1H17 and beyond by Zacks
- PURE: Withdrawal of FCN has only limited short term impact on revenue growth; strong revenue growth is still expected in fiscal 2015 and beyond, a reborn company with new focus on food safety maintaining Outperform by Zacks
- PURE: Business is going to take off in calendar 2014, a reborn company with new focus on food safety Outperform by Zacks
- Pressure BioSciences Reports First Quarter 2011 Results by Zacks
- Pressure BioSciences Reports Strong Third Quarter Financial Results by Zacks
- Product sales may take longer time to gain traction by Zacks
- Q1 Results, Supplemental Trial Gearing Up by Zacks
- Q3 Results. Financing Update by Zacks